- American Board of Psychiatry and Neurology - Psychiatry & Neurology
- University of Calgary, 1983
Residencies & Internships
- Montreal Neurological Hospital & Institute, Neurology-Vascular, 1988
- Foothills Medical Center, 1985
- Ludwig Institute For Cancer Research, Cellular and Molecular Biology, NY, 1992
Member of the Henry Ford Cancer Institute
Dr. Mikkelsen received his MD from the University of Calgary, Canada and completed clinical training in neurology at the Montreal Neurologic Institute. Following this, he did post-doctoral training in tumor and molecular biology at the Ludwig Institute for Cancer Research in Montreal and then in La Jolla, California. Since 1992, he has led the brain tumor program at Henry Ford Hospital, responsible for building the clinical trials program and laboratory of tumor biology. Together with Dr. Kalkanis and other scientists, he helped assemble what has become the Hermelin Brain Tumor Center, a basic and clinical research resource for patients in Michigan and surrounding states.
As Director of the Medical Neuro-Oncology Clinic, Dr. Mikkelsen leads the weekly Tumor Board as well as multiple clinical trials for brain tumor patients.
The internet age has been empowering for many patients dealing with a new diagnosis of a brain tumor. However, there is way too much unfiltered content and it takes a real multidisciplinary team to partner with a patient and their family in order to formulate the best plan of care. We have access to many novel and innovative approaches to treatment to compliment current state-of-the-art treatment. The goal, of course, is to maximize the quality of a person's life, despite the challenges. This means emotionally, mentally and physically. I pride myself on engaging a patient, the team and moving ahead in the most promising way possible.
Hermelin Brain Tumor Bank and Personalized Brain Tumor Therapy: The Center is a leader in the understanding of the genetics of brain tumors, and in the development of therapies matched to each patient's brain tumor genetics for the best chance at recovery. The Center is a major contributor to The Cancer Genome Atlas -- a national cooperative of major academic medical centers sponsored by the National Institutes of Health, responsible for identifying certain survival-related genes. The data generated from the TCGA and the 1000 tumor tissues in the tumor bank are a major resource for each of the Hermelin Brain Tumor Center's (HBTC) research laboratories. HBTC resources constitute some 40% of resources in the national TCGA program
Brain Tumor Neuro-imaging: Dr. Mikkelsen's laboratory has collaborated extensively with small animal imaging, clinical neuroradiology, and image analysis for pre-clinical and clinical brain tumor studies, primarily using perfusion CT and multiple MRI techniques. The long-term goal is to validate imaging biomarkers as measures of therapeutic response toward targeted therapies.
Dr. Mikkelsen works closely with Dr. Tobias Walbert and Dr. Jim Snyder, Neuro-Oncology colleagues, with clinical research interests focus on outcomes research.
Award and Honors
I received additional, examined, certification from the United Council of Neurologic Subspecialties of NeuroOncology in 2012.
I have authored 175 publications and co-edited a text book on brain tumor invasion.
He was also selected a “Top Doc” in 2003, 2004, 2005, 2006 & 2007
Best Doctors for Oncology in 2007 and 2008.